Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Trump Presidency -- Ignore unavailable to you. Want to Upgrade?

To: Lane3 who wrote (164670)	5/19/2020 6:53:57 AM
From: combjelly	Read Replies (1) \| Respond to of 361410

Long before you get to such a trial, you have to show some sort of results on tissue cultures. If you can show some results and can formulate a mechanism by which it does what you think it does, then you can proceed. The next step is to move to animal trials. Because what works in a tissue culture doesn't necessarily work in a whole animal. If you pass those hurdles, then you have a shot at getting something approved by an ethics panel for prophylactic use. You can skip a step or so if you are dealing with terminal patients who have exhausted all other treatments. In general though, you need to have shown some sort of effectiveness in tissue cultures and have a good idea of why it is doing what you claim. "It just works" won't get you far. At least in the US. Some other countries aren't quite as skittish as in the US when dealing with humans. Considering i-node claims to know how research is done in this country, he should know this. Heck, even research on some animals like primates needs to be reviewed by an ethics panel. As you note, the ethics of randomly dosing people, even volunteers, is a dicey area.